Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Recommendation of “Buy” from Brokerages

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been assigned an average recommendation of “Buy” from the fifteen research firms that are covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $21.45.

Several equities analysts recently issued reports on the company. Mizuho reaffirmed a “neutral” rating and issued a $18.00 price objective (up from $14.00) on shares of Sucampo Pharmaceuticals in a research report on Wednesday, January 3rd. Maxim Group cut Sucampo Pharmaceuticals to a “hold” rating in a research report on Monday, January 1st. ValuEngine raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 31st. UBS Group cut Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a research report on Friday, January 5th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $15.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Tuesday, January 2nd.

Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $17.95 on Friday. The stock has a market capitalization of $849.02, a P/E ratio of -5.46, a P/E/G ratio of 5.06 and a beta of 1.45. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $18.75. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The business had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.30 EPS. equities analysts anticipate that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.

In other news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the transaction, the insider now directly owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.13% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Trexquant Investment LP bought a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at $122,000. Nine Chapters Capital Management LLC purchased a new stake in shares of Sucampo Pharmaceuticals in the 3rd quarter worth $127,000. JPMorgan Chase & Co. purchased a new stake in shares of Sucampo Pharmaceuticals in the 2nd quarter worth $117,000. Aperio Group LLC purchased a new stake in shares of Sucampo Pharmaceuticals in the 3rd quarter worth $137,000. Finally, SG Americas Securities LLC increased its stake in shares of Sucampo Pharmaceuticals by 5.6% in the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 631 shares in the last quarter. 64.55% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Recommendation of “Buy” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/20/sucampo-pharmaceuticals-inc-scmp-receives-average-recommendation-of-buy-from-brokerages-2.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply